Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Anti-CD19/CD20/CD22 CAR-T Cells |
Synonyms | |
Therapy Description |
Anti-CD19/CD20/CD22 CAR-T cells are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19, CD20, and CD22, which may induce antitumor activity (Blood (2022) 140 (Supplement 1): 7474–7475). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Anti-CD19/CD20/CD22 CAR-T Cells | CD19 Immune Cell Therapy 65 CD20 Immune Cell Therapy 13 CD22 Immune Cell Therapy 15 | Anti-CD19/CD20/CD22 CAR-T cells are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19, CD20, and CD22, which may induce antitumor activity (Blood (2022) 140 (Supplement 1): 7474–7475). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05418088 | Phase I | Cyclophosphamide + Fludarabine Anti-CD19/CD20/CD22 CAR-T Cells | Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies | Recruiting | USA | 0 |
NCT06879340 | Phase I | Cyclophosphamide + Fludarabine Anti-CD19/CD20/CD22 CAR-T Cells | Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients with Relapsed or Refractory B-cell Malignancies | Recruiting | USA | 0 |